natgillin/translations-raw huggingface dataset:
Emb-29: The method according to any of Emb-26 to Emb-28, where dose a is within the range of from 10 to 90 wt.-% of dose b. 
Tapentadol prema patentnom zahtjevu 1 ili 2, naznačen time da je doza a unutar raspona od 10 do 90 % po težini doze b.
passing through the filtration material a basic flow at pH > 10 and recirculating it through said material for a time sufficient to saturate it with arsenic, 
naknadno se kroz materijal za filtriranje propušta bazični tok s pH >10, te recirkulira kroz navedeni materijal kroz vrijeme dovoljno za njegovo zasićivanje arsenom, -
After 4 days small brown spots appeared on the untreated bananas and became numerous and large on day 5. 
Poslije 4 dana sitne smeđe točke su se javile na netretiranim bananama, a postale su brojne i krupne na dan 5.
A compound as claimed in claim 6, wherein R1 represents C1-C6 alkyl-R20 and R20 is an aryl, heteroaryl or heterocyclyl group, any of which may optionally be substituted as set out in claim 1; 
Spoj u skladu s patentnim zahtjevom 6, naznačen time što R1 predstavlja C1-6alkil-R20, a R20 je arilna, heteroarilna ili heterociklilna skupina, od kojih bilo koja može izborno biti supstituirana kao što je iznijeto u patentnom zahtjevu 1;
Atomiser according to one of the preceding claims, characterised in that the first and/or second locked state is not reversible, and/or that the pressurisation or atomisation is mechanically driven, in particular without propellant gas, preferably by spring power, and/or that the atomiser (1) is a portable inhaler, in particular for medicinal aerosol therapy. 
Raspršivač prema jednom od prethodnih zahtjeva, naznačen time, da se zatvoreno stanje ne može vratiti na početak, i/ili da se tlačenje ili raspršivanje provodi na čisto mehanički način, posebno bez pogonskog plina, poželjno pomoću snage opruge, i/ili da je raspršivač (1) konstruiran kao prijenosni inhalator, posebno za medicinsku aerosolnu terapiju.
Ship-like object according to claim 14, having a top transverse plate (2) extending at an angle (B) obliquely upwards, wherein said angle (B) is dependent of a distance between a hull of the ship-like object and the top transverse plate (2). 
Objekt sličan brodu u skladu s patentnim zahtjevom 14, ima gornju poprečnu ploču (2) koja se pod kutem ((B) nastavlja koso prema gore, pri čemu je navedeni kut (B) ovisan o udaljenosti između trupa objekta sličnog brodu i gornje poprečne ploče(2).
at least one high molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight selected from 4,000,000 and 7,000,000; and 
najmanje jedan polietilen oksid koji ima. prema teološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000; i
The antibody or antigen-binding fragment or pharmaceutical composition for use according to any one of claims 4 to 6, wherein the use in medicine is the use in a method for the treatment of inflammatory bowel disease. 
Protutijelo ili njegov fragment koji veže antigen ili farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 6 do 9, naznačeni time, da se kod uporabe u medicini radi o uporabi u postupku liječenja bolesti ulcerativnog kolitisa.
Use according to claim 7, characterized in that the composition is applied on a cigarette paper as partial coating, in the form of bands parallel to each other and arranged perpendicularly to the longitudinal axis of the smoking article. 
Uporaba u skladu s patentnim zahtjevom 5, naznačena time što se kompozicija nanosi na papirni omotač proizvoda (25) za pušenje kao djelomični premaz (1a), u obliku traka koje su međusobno paralelne i raspoređene na uzdužnu os proizvoda (10) za pušenje.
Moreover, the processes according to the invention can be varied in a preferred manner such that materials being different from wood are inserted or incorporated into the block of wood, which is obtained by the gluing of the pieces of wood. 
Osim toga, postupak koji je u skladu s ovim izumom može se mijenjati na prikladan način tako da se materijali koji su različiti od drva umetnu ili ugrade u blok od drva koji je dobiven lijepljenjem komada od drva.
The pharmaceutically acceptable composition of clause (10), wherein the agent is selected from ascorbic acid, Na-ascorbate, L-cysteine, N-acetylcysteine (NAC), gluthatione (GSH), Na2-EDTA, Na2-EDTA-Ca, or combinations thereof. 
Farmaceutski prihvatljiv tekući sastav iz zahtjeva 4, naznačeno time da je agent L-cistein, N-acetilcistein (NAC), glutation (GSH), Na,-EDTA, Na;-EDTA-Ca, natrijev bisulfit, ili kombinacije istih.
Total number of windings 
Broj međunarodne objave:
For this purpose the heat exchanger 70 can be removed from the chamber 2 and can be placed in a dishwasher or other cleaning installations or can be cleaned manually. 
U tu svrhu, izmjenjivač topline 70 se može odvojiti od komore 2 i može se postaviti u perilicu suđa ili neki drugi uređaj za čišćenje ili se može očistiti ručno.
providing an array former; and dressing the garment material on the array former before applying the coating; and then curing the layer of coating; and stripping the garment material from the array former. 
dodavanja stvaratelja matriksa; i apretiranja odjevnog materijala na stvaratelju matriksa prije stavljanja obloge; i zatim stvrdnjavanja sloja obloge; i skidanja odjevnog materijala sa stvaratelja matriksa.
After 5min, 2N aqueous sodium carbonate (65 ml, 130mmol) solution was added, followed by 4-chlorophenylboronic acid (7.16g, 45.8 mmol). 
Nakon 5 min dodana je 2N vodena otopina natrijeva karbonata (65 mL, 130 mmol), nakon čega je uslijedila 4-klorofenilborna kiselina (7.16 g, 45.8 mmol).
Interleukin-18 binding protein (IL-18BP) is a naturally occurring soluble protein that was initially affinity purified, on an IL-18 column, from urine (Novick et al. 
Vezni protein interleukin-18 (IL-18BP) je prirodni topljivi protein koji je prvotno bio pročišćen afinitetno na TL-18 koloni iz mokraće (Novick i sur., 1999.
the Al-2 region corresponds to a region in native mature human FVIII from about amino acid 201 to about amino acid 232 or from about amino acid 218 to about amino acid 229 of SEQ ID NO:1, 
A1-2 regija odgovara regiji u nativnom zrelom humanom FVIII od oko aminokiseline 201 do oko aminokiseline 232 ili od oko aminokiseline 218 do oko aminokiseline 229 u SEQ ID NO:1,
A pharmaceutical combination of Claim 25 wherein the anti-depressant agent is selected from norepinephrine reuptake inhibitors selected from tertiary and secondary amine tricyclics; selective serotonin reuptake inhibitors selected from fluoxetine, fluvoxamine, paroxetine and sertraline; monoamine oxidase inhibitors selected from isocarboxazid, phenelzine, tranylcypromine and selegiline; reversible inhibitors of monoamine oxidase including moclobemide; serotonin and norepinephrine reuptake inhibitors including venlafaxine; corticotropin releasing factor receptor antagonists; alpha-adrenoreceptor antagonists; and atypical antidepressants selected from bupropion, lithium, nefazodone, trazodone and viloxazine. 
Farmaceutski sastav Zahtjeva 25, naznačen time, da je antidepresivno sredstvo odabrano od inhibitora reapsorpcije norepinefrina odabranih od tricikličkih tercijarnih i sekundarnih amina, selektivnih inhibitora reapsorpcije serotonina odabranih od fluoksetin, fluvoksamin, paroksetin i sertalina, inhibitora monoamin oksidaze odabranih od izokarboksazid, fenelzin, tranilcipromin i selegilina, reverzibilnih inhibitora monoamin oksidaze uključujući moklobemid, inhibitora reapsorpcije serotonina i norepinefrina uključujući venlafaksin, antagonista faktora receptora za oslobađanje kortikotropina, antagonista alfa-adrenoreceptora i atipičnih antidepresiva odabranih od bupropin, litij, nefazodon, trazodon i viloksazina.
Others can be readily synthesized by methods known in the art, and as described below. 
Ostale je moguće sintetizirati metodama poznatima struci, i kako je opisano u nastavku.
The method of claim 8, further comprising administering to the subject at least one adjuvant. 
Sastav cjepiva za uporabu prema zahtjevu 7, pri čemu je barem jedan adjuvans za primjenu na subjektu.
A Plastoferrite plate, magnetised in a direction perpendicular to the surface (model M100.8, Maurer magnetics AG, CH-8627 Grüningen), was engraved on a computer-controlled mechanical engraving station with text of different sizes (see FIG. 2 a). 
Na ploču izrađenu od Plastoferrita, koja je magnetizirana u smjeru okomito na površinu (model M100.8, Maurer magnetics AG, CH-8627 Groningen), ugraviran je tekst različite veličine na računalno nadziranoj mehaničkoj postaji za graviranje (vidi Sliku 2a).
This invention relates to the use of dihydrotetrabenazine in treating Huntington's Disease. 
Ovaj izum se odnosi na uporabu dihidrotetrabenazina u liječenju Huntington-ove bolesti.
The therapeutic hosiery item according to one or more of the preceding claims, characterized in that the coating yarn or yarns of said elastomer yarn (1a) of said first rows of knitting (1) is or are made of natural or polyamide fibers. 
Terapeutska čarapa prema jednom ili više prethodnih zahtjeva, naznačena time, da je konac za prevlačenje ili da su konci za prevlačenje spomenutog elastomernog konca (1a) spomenutih neparnih redova pletiva (1) izrađeni od prirodnih vlakana ili od poliamidnih vlakana.
Providing granulated darunavir by; mixing water and Hypromellose, spraying this first mixture on a powder of darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and drying the so obtained darunavir granulate 
- osiguravanje granuliranog darunavira miješanjem vode i Hipromeloze, raspršivanje ove prve smjese na prašak darunavira i/ili na njegovu farmaceutski prihvatljivu sol ili njegov solvat, te sušenje tako dobivenog granuliranog darunavira,
an anti-CD22 antibody comprising an HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:6 and an HVR-H1 comprising an amino acid sequence selected from SEQ ID NO:2; 
(iii) obuhvaća jaki lanac pune duljine, koji ima aminokiselinsku sekvencu SEQ ID NO:88 1 slabi lanac pune duljine, koji ima aminokiselinsku sekvencu SEQ ID NO:87; ili
A method of treating a mammal having a cancer characterized by having a defect in the homologous recombination (HR) pathway of double-stranded DNA repair, comprising administering to said mammal a compound of Formula (I) or a pharmaceutically acceptable salt thereof: wherein R is 
Spoj prema bilo kojem zahtjevu od 1-5, ili farmaceutski pripravak prema bilo kojem zahtjevu od 6-8, naznačen time da je za uporabu za liječenje sisavca koji ima rak koji se odlikuje time da ima defekt u putu popravka homologne rekombinacije (HR) dvolančane DNA
The apparatus according to claim 1, wherein the elongated ferrous object comprises a rope of a hoisting machinery, including a hoisting machinery in a crane, a ropeway, an elevator, a conveyor in a mine shaft or a ski lift. An arrangement comprising one or more elongated objects for hoisting payload and 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da izduženi željezni predmet (302) obuhvaća kabel sustava za podizanje, na primjer sustav za dizanje u dizalici, kao što je portalna dizalica ili mostna dizalica, žičara, dizalo, transportna traka u rudniku ili ski lift.
Modular elements as claimed in claim 7, characterised in that said capturing elements (92) are connected to a header (112,114). 
Modularni elementi u skladu s patentnim zahtjevom 7, naznačeni time što su navedeni elementi za skupljanje (92) spojeni na kolektor (112, 114).
A compound according to claim 8 selected from the group: 
Spoj prema zahtjevu 20 naznačen time da je odabran iz slijedeće skupine:
The composition of claim 6, wherein the polypeptide consists of the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 4. 
Sastav iz bilo kojeg od patentnih zahtjeva 1 do 5, pri čemu polipeptid ima slijed kako je navedeno u SEQ ID NO:2 1li SEQ ID NOÂ«4.
The method of claim 4, wherein the second medicament is another antibody, a chemotherapeutic agent, a cytotoxic agent, an anti-angiogenic agent, an immunosuppressive agent, a prodrug, a cytokine, a cytokine antagonist, cytotoxic radiotherapy, a corticosteroid, an anti-emetic, a cancer vaccine, an analgesic, or a growth-inhibitory agent. The method of claim 4, wherein the second medicament is tamoxifen, letrozole, exemestane, anastrozole, irinotecan, cetuximab, fulvestrant, vinorelbine, erlotinib, bevacizumab, vincristine, imatinib, sorafenib, lapatinib, or trastuzumab. 
Anti-Notch1-NRR-protutijelo za uporabu prema zahtjevu 20, naznačeno time, da drugi lijek je (1) neko drugo protutijelo, kemoterapeutsko sredstvo, cititoksično sredstvo, anti-angiogensko sredstvo, imunosupresivno sredstvo, prolijek, citokin, antagonist citokina, citotoksična radioterapija, kortikosteroid, anti-emetik, cjepivo protiv raka, analgetik ili sredstvo inhibicije rasta, ili (11) tamoksifen, letrozol, eksemestan, anastrozol, irinotekan, cetuksimab, fulvestrant, vinorelbin, erlotinib, bevacizumab, vinkristin, imatinib, sorafenib, lapatinib ili trastuzumab.
The paper sheet according to one or more of the preceding claims, wherein said active ingredient is a glycolic extract of Aloe Barbadensis. 
List papira prema jednom ili više od prethodnih zahtjeva, naznačen time, da sadrži dodatni aktivni sastojak koji je sredstvo protiv insekata.
in the presence of a base, to provide a compound of the formula: 
Spoj formule F [image] gdje R’ je OH ili Cl;
The composition for use according to claim 6 or the compound for use according to any of claims 7-10, wherein the cancer is non-small cell lung cancer, ovarian cancer, breast cancer, cervical cancer, pancreatic cancer, prostate cancer, stomach cancer, brain cancer, liver cancer, metastatic cancer, or testicular cancer. 
Inhibitor tirozin hidroksilaze, promotorski spoj za melanin, promotorski spoj za p450 3A4 ili inhibitor leucin aminopeptidaze za uporabu prema bilo kojem od patentnih zahtjeva 2-5, naznačen time što je rak odabran od raka dojke, raka pluća ne malih stanica, raka jajnika, raka grlića maternice, raka gušterače, raka želuca, raka mozga, raka jetre, raka testisa, leukemije ili limfoma.
The method according to claim 1, wherein, during injection of said sterile washing solution, the washing and separating container is held in a vertical position with said outlet facing toward the ground. 
Metoda u skladu sa patentnim zahtjevom 1 ili 2, naznačena time da se tokom ubrizgavanja navedene sterilne otopine za ispiranje spremnik (1) drži u vertikalnoj poziciji sa njegovim odvodom (103) usmjerenim ka i paralelnim sa tlom.
detecting the presence of the signal from the complex formed in the test region comprising the first detectable entity and the second detectable entity, wherein the presence of the signal is indicative of the presence of the antibody in the test sample. 
(c) detektiranju prisutnosti signala iz prvog detektibilnog entiteta u ispitivanom području, gdje prisutnost signala ukazuje na prisutnost protutijela u ispitivanom uzorku.
Evaporation of the collected column fractions of interest and removal of the solvent at reduced pressure gave a pink solid (6.53 g) 
Evaporacija sakupljenih poželjnih kolonskih frakcija i uklanjanje otapala uz smanjeni tlak daje ružičastu krutinu (6.53
The antibody or antigen-binding fragment thereof according to claim 1, wherein the reference antibody comprises a heavy chain and a light chain defined by one of the following pairs of sequences: 
Monoklonsko protutijelo ili njegov antigen-vezujući fragment prema patentnom zahtjevu 1, naznačeno time što referentno protutijelo sadrži teški lanac i lagani lanac definiran jednim od sljedećih parova sekvenci:
applying an underpressure within the space sealed by said sheets, 
- < primjena podtlaka unutar prostora zabrtvljenog navedenim plohama,
trifluoromethyl, O-alkyl1, carboxyl, cyano, nitro, formyl, hydroxy, NH-alkyl1, N(alkyl1)(alkyl1), and amino, the latter nitrogen substituents optionally in the form of a basic nitrogen functionality, or 
(vi) trifluorometil, O-alkil', karboksil, cijano, nitro, formil, hidroksi, NH-alkil', N(alkil')(alkil') i amino grupe, od kojih su potonji azidni supstituanti fakultativno u obliku odgovarajuće osnovne azidne funkcije, ili
a heavy chain comprising a human IgG4 heavy chain constant region and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:37; and 
varijabilnu regiju teškog lanca koja sadrži sekvencu aminokiselina navedenu u SEQ ID NO:37 i varijabilnu regiju lakog lanca koja sadrži sekvencu aminokiselina navedenu u SEQ ID NO:43;
The pharmaceutical composition for use of claim 7 or 8, wherein a second therapeutic agent is administered to the subject before, after, or concurrent with the initial dose and/or the secondary dose of the pharmaceutical composition, wherein, preferably, the second therapeutic agent is selected from the group consisting of: a TNF inhibitor, an IL-1 inhibitor, an IL-5 inhibitor, an IL-8 inhibitor, an IgE inhibitor, a leukotriene inhibitor, a corticosteroid, a methylxanthine, an NSAID, nedocromil sodium, cromolyn sodium, a long-acting beta2 agonist, an anti-fungal agent, and a combination thereof. 
Farmaceutski pripravak za uporabu prema zahtjevu 7 ili 8, naznačen time što se drugo terapijsko sredstvo daje subjektu prije, poslije, ili istodobno s početnom dozom i/ili sekundarnom dozom farmaceutskog pripravka, pri HR P20181963 T1 čemu je, poželjno, drugo terapijsko sredstvo odabrano iz skupine koja sadrži: inhibitor TNF, inhibitor IL-I, inhibitor IL-5, inhibitor IL-8, inhibitor IgE, inhibitor leukotriena, kortikosteroid, metilksantin, NSAID, nedokromil natrij, kromolin natrij, dugo djelujući beta2 agonist, antigljivično sredstvo, te njihovu kombinaciju.
for the preparation of a medicament for the treatment of a Hepatitis C infection. The use of claim 1, wherein R7 is H and R1 is a monophosphate, a diphosphate, or a triphosphate. 
(2'R)-2'-deoksi-2'-fluoro-2'-C-metil nukleozid (B-D ili B-L) iz patentnog zahtjeva 1 ili njegova farmaceutski prihvatljiva sol, u kojima R7 je H i R1 je monofosfat, difosfat, ili trifosfat.
Preferably, the hydrocarbon source subjected to cracking (step a)) is chosen from the group consisting of naphtha, gas oil, natural gas liquid, ethane, propane, butane, isobutane and mixtures thereof. 
Postupak prema zahtjevu 1, naznačen time da je izvor ugljikovodika odabran iz skupine koja se sastoji od nafte, plinskog ulja, prirodnog tekućeg plina, etana, propana, butana, izobutana i njihovih mješavina.
said first pawl rides over one of said plurality of teeth during said return stroke. A counter according to any one of claims 25 to 27, wherein said first and second pawls are integral with said first ring member, and said plurality of teeth are disposed on a teeth-bearing member arranged to be reciprocally moveable within the bore of said first ring member, and wherein said pawl-and-teeth mechanism is configured such that reciprocal movement of the teeth-bearing member within the bore of the first ring member causes rotational movement of the first ring member. 
Brojač u skladu sa bilo kojim od prethodnih patentnih zahtjeva 21 do 23, gdje su navedene prva i druga zapinjača (402a, 402b) integralne sa navedenim prvim prstenastim članom (201), i navedeni veliki broj zuba (210) je razmješten na članu koji nosi zube (206) organiziran da bude recipročno pokretan unutar bušotine navedenog prvog prstenastog člana, i gdje je navedeni mehanizam sa zubima i zapinjačom konfiguriran tako da recipročni pokret člana koji nosi zube unutar bušotine prvog prstenastog člana uzrokuje rotacijski pokret prvog prstenastog člana.
R11' and R11" are independently selected from hydrogen and C1-3alkyl optionally substituted by hydroxyl, halo, C1-3alkoxy, carboxy or cyano) or R11' and R11" together with the nitrogen atom to which they are attached form a 4-7 membered ring; 
' i R11" su nezavisno odabrani od vodika i C1-3alkila opcionalno supstituirani sa hidroksilom, halo, C1-3alkoksi, karboksi ili cijano) ili R11' i R11" zajedno sa atomom dušika na koji su spojeni tvore 4-7 člani prsten;
An eccentric adjustment element according to claim 1, wherein the force introducing device is configured to receive an exterior force. 
Ekscentrični element za prilagodbu (10) prema zahiljevu 4, naznačen time što je naprava za uvođenje sile (22) napravljena kao vanjska naprava za uvođenje sile.
A compound according to claim 32 wherein R4 is phenyl substituted at the 4-position with hydroxy, C1-3alkylaminocarbonyl, or aminocarbonyl, and substituted at the 2- and 6-positions with methyl substituents. 
Spoj prema zahtjevu 32 naznačen time da R* je fenil supstituiran na 4-poziciji sa hidroksi, C,salkilaminokarbonil ili aminokarbonil i supstituiran na 2-poziciji i 6-poziciji sa metil supstituentima.
or an N-oxide or agriculturally acceptable salt thereof. 
XjeN, CH ili CF; ili njegov N-oksid ili njegova agrikulturno prihvatljiva sol.
one of R9a and R9b is hydrogen and the other of R9a and R9b is seleced from: 
(1) bilo koji od njih je vodik, a drugi je:
The liquefied gas treatment system according to claim 1, wherein the compressor (13,13a,13b) is a multi-stage compressor including a plurality of compression means (14,14a,14b). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što kompresor (150;13) sadrži više kompresijskih cilindara (14).
In one embodiment, the pharmaceutical composition is an aqueous liquid. In one embodiment, the pharmaceutical composition further comprises: water-for-injection, aqueous saline solution, aqueous glucose solution, saline for injection/infusion, glucose for injection/infusion, Ringer's solution, or lactated Ringer's solution. 
Farmaceutski sastav prema zahtjevu 11 1li 12, naznačen time, da nadalje sadrži: vodu za injekciju, vodenu solnu otopinu, vodenu otopinu glukoze, vodenu otopinu soli za injekciju/infuziju, glukozu za injekciju/infuziju, Ringer-ovu otopinu, ili mliječnu Ringer-ovu otopinu.
Equilibration buffer: PBS—flow rate 1 ml/min. 
Pufer za ekvilibriranje: PBS - brzina protoka 1 ml/min.
In one aspect, the invention provides a method for enhancing expression of recombinant protein in cell culture comprising culturing cells that express the recombinant protein in culture media comprising an amount of alkyl-amine-n-oxide (AANOx) sufficient to improve the growth rate of the cells in culture. 
Postupak poboljšavanja eksprimiranja rekombinantnog čimbenika zgrušavanja krvi u kulturi stanica koja sadrži uzgajane stanice koje eksprimiraju rekombinantni čimbenik zgrušavanja krvi u mediju za uzgoj u kulturi koja sadrži količinu alkil-amin-N-oksida (AANOx) dovoljna za poboljšavanje stope rasta stanica u kulturi, naznačen time što se količina AANOx kreće između 4 i 80 ppb, te
The method of any one of claims 1-6, wherein the IgG1 antibody comprising a VH region of the amino acid sequence of SEQ ID NO:5 and a VL region of the amino acid sequence of SEQ ID NO:6. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 od 6, naznačen time, da IgG1 protutijelo sadržava VH područje aminokiselinske sekvence SEQ ID NO: 5 i VL područje aminokiselinske sekvence SEQ ID NO: 6.
A "unit dosage form" is a physically discrete unit containing a unit dose suitable for administration in human subjects or other mammals. 
"Oblik jedinice doziranja" je fizički diskretna jedinica, koja sadrži jediničnu dozu pogodnu za primjenu na ljudskim pacijentima ili drugim sisavcima.
A peptide consisting of the amino acid sequence according to SEQ ID No. 1. 
PATENTNI ZAHTJEVI 1. = Peptid koji se sastoji od slijeda aminokiselina prema SEQ ID No. 22.
A pharmaceutical composition according to claim 28, additionally comprising other active ingredients. 
Farmaceutski pripravak prema zahtjevu 22, naznačen time što dodatno sadrži druge aktivne sastojke.
The route of administration will depend upon the condition to be treated but preferred compositions are formulated for oral, nasal, bronchial or topical administration. 
Sastav prema zahtjevu 17, naznačen time, da je za oralnu, nazalnu, bronhijalnu ili topikalnu primjenu.